Hydrolysis Order Remained Untested in the Urinary Cannabinoid Protocol
The researchers used combined enzymatic and basic hydrolysis but did not evaluate whether reversing their order would change the result. A successful preparation procedure does not establish that alternative sequences are equivalent.
Preparation defined the measured material
The urinary CBD study analyzed several parent cannabinoids and metabolites by LC–MS/MS. Conjugated urinary compounds required consideration during preparation. The paper also distinguished analytical procedures used for six participants from an earlier pilot and twelve participants newly reported in the expanded study.
Optimization had a specific boundary
The authors stated that laboratory optimization supported their combined hydrolysis procedures, while naming the order of enzymatic and base treatment as unevaluated. That limitation is not evidence that a different order necessarily fails. It means the study cannot be cited as directly demonstrating equivalence of both sequences. Conjugate structure and preparation conditions can matter to what becomes measurable.
What another method must show
A laboratory adopting a different sequence should rely on validation of its own workflow, including relevant conjugated controls and analyte-specific performance. It should not borrow the expanded study’s biological findings as proof that its preparation is interchangeable. The resulting concentration describes a defined urine measurement; the hydrolysis procedure does not itself establish timing of use or functional impairment.
Related analysis: the urinary CBD route comparison.
Research cited
Sholler and colleagues (2021). Urinary Pharmacokinetic Profile of Cannabidiol, THC and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. DOI: 10.1093/jat/bkab059.
